

Daniele Altomare

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8093708/publications.pdf>

Version: 2024-02-01

41
papers

1,906
citations

361045

20
h-index

301761

39
g-index

43
all docs

43
docs citations

43
times ranked

2563
citing authors

#	ARTICLE	IF	CITATIONS
1	Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study. <i>Alzheimer's and Dementia</i> , 2023, 19, 844-856.	0.4	6
2	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. <i>Alzheimer's and Dementia</i> , 2022, 18, 29-42.	0.4	24
3	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. <i>Nature Reviews Neuroscience</i> , 2022, 23, 53-66.	4.9	203
4	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. <i>Magnetic Resonance Imaging</i> , 2021, 76, 108-115.	1.0	24
5	Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2200-2211.	3.3	19
6	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2157-2168.	3.3	18
7	Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 105.	3.0	15
8	Societal and equity challenges for Brain Health Services. A user manual for Brain Health Services" part 6 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 173.	3.0	14
9	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services" part 2 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 169.	3.0	35
10	Dementia risk communication. A user manual for Brain Health Services" part 3 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 170.	3.0	21
11	Protocols for cognitive enhancement. A user manual for Brain Health Services" part 5 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 172.	3.0	15
12	Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services" part 1 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 168.	3.0	26
13	Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services" part 4 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 171.	3.0	37
14	Towards fingerprinting and identifiability within the Alzheimer's™ continuum using resting-state functional connectivity. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
15	Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's™ disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 270-280.	3.3	23
16	Multitracer model for staging cortical amyloid deposition using PET imaging. <i>Neurology</i> , 2020, 95, e1538-e1553.	1.5	55
17	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. <i>Alzheimer's and Dementia</i> , 2020, 16, 1457-1468.	0.4	43
18	Impact of the disclosure of amyloid-PET results to patients with subjective cognitive decline: the AMYPAD Diagnostic and Patient Management Study (DPMS). <i>Alzheimer's and Dementia</i> , 2020, 16, e040952.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Baseline features of the AMYPAD Diagnostic and Patient Management Study (DPMS) participants. <i>Alzheimer's and Dementia</i> , 2020, 16, e042628.	0.4	1
20	Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): Retrospective analyses on the Geneva Memory Clinic cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e045436.	0.4	1
21	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2020, 16, 750-758.	0.4	29
22	Comparison of visual criteria for amyloid-PET reading: could criteria merging reduce inter-rater variability?. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 414-421.	0.4	5
23	IS A LARGE-SCALE SCREENING FOR ALZHEIMER'S DISEASE POSSIBLE? YES, IN A FEW YEARS. <i>Journal of prevention of Alzheimer's disease</i> , The, 2019, 6, 1-2.	1.5	3
24	Medial temporal lobe atrophy and posterior atrophy scales normative values. <i>NeuroImage: Clinical</i> , 2019, 24, 101936.	1.4	12
25	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , 2019, 266, 2535-2545.	1.8	11
26	Applying the ATN scheme in a memory clinic population. <i>Neurology</i> , 2019, 93, e1635-e1646.	1.5	51
27	AMYPAD Diagnostic and Patient Management Study: Rationale and design. <i>Alzheimer's and Dementia</i> , 2019, 15, 388-399.	0.4	37
28	Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid PET. <i>Alzheimer's and Dementia</i> , 2018, 14, 1088-1098.	0.4	15
29	Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1557-1566.	3.3	35
30	Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1470-1486.	3.3	19
31	Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1546-1556.	3.3	24
32	Clinical utility of FDG-PET for the clinical diagnosis in MCI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1497-1508.	3.3	61
33	Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1534-1545.	3.3	86
34	Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1487-1496.	3.3	35
35	European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain ¹⁸ F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. <i>European Journal of Neurology</i> , 2018, 25, 1201-1217.	1.7	153
36	Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease with Transcranial Magnetic Stimulation. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 221-230.	1.2	44

#	ARTICLE	IF	CITATIONS
37	Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1509-1525.	3.3	81
38	Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1526-1533.	3.3	28
39	Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment. <i>JAMA Neurology</i> , 2016, 73, 1417.	4.5	84
40	Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic?. <i>Neurodegenerative Diseases</i> , 2016, 16, 111-117.	0.8	6
41	Brain atrophy in Alzheimer's Disease and aging. <i>Ageing Research Reviews</i> , 2016, 30, 25-48.	5.0	507